Klotho

Klotho is a gene, and the protein it encodes, whose loss in mice produces a syndrome of early-onset frailty and whose overexpression lengthens mouse lifespan. Its best-demonstrated job is unglamorous: α-klotho is the co-receptor that lets the bone hormone FGF23 act on the kidney and regulate phosphate. The longevity reading of klotho rests on mouse genetics, human association studies that replicate unevenly, and one memory experiment in aged rhesus monkeys. Nothing has yet been reported about what klotho does when given to a person.

§Overview

The KL gene encodes α-klotho, a single-pass transmembrane protein expressed most heavily in the kidney tubule, the parathyroid gland and the choroid plexus. Its large extracellular domain is cleaved by cell-surface proteases and released into blood, urine and cerebrospinal fluid, so the same gene yields a local receptor component and a circulating hormone. A paralogue, β-klotho, performs the equivalent co-receptor job for the metabolic hormones FGF21 and FGF19, which makes the klotho proteins the shared hardware of an endocrine system rather than a single anti-aging switch.¹

That distinction matters for how the subject is discussed. Most of the interest in klotho concerns the shed, soluble form and its supposed systemic effects; most of the mechanism that is actually worked out concerns the membrane form and mineral metabolism. Reviews and press coverage frequently blur the two.

§Discovery and naming

Klotho was found by accident. A group led by Makoto Kuro-o was working on a transgenic mouse line when an insertion disrupted an unidentified gene, and the resulting homozygous animals were short-lived and showed arteriosclerosis, skin atrophy, osteoporosis, emphysema and infertility.² The gene was named for Klotho, the Fate of Greek myth who spins the thread of life.

1. 1997
   Gene identified in mice
   Kuro-o and colleagues report that disrupting a previously unknown mouse gene produces a short-lived animal with multiple features resembling human aging.
2. 2002
   A human haplotype
   Arking and colleagues describe KL-VS, a klotho variant carrying two amino-acid substitutions, and report that homozygous carriers are underrepresented among elderly people in three populations.
3. 2005
   Overexpression extends mouse lifespan
   Transgenic mice carrying extra klotho from conception live longer than controls, and the protein is shown to repress insulin and IGF1 signalling.
4. 2006
   The receptor job
   Klotho is shown to convert a canonical FGF receptor into a specific receptor for FGF23, placing the protein at the centre of phosphate regulation.
5. 2010
   Phosphate reinterpretation
   Blocking phosphate retention in klotho-null mice reverses most of the premature-aging phenotype, and a high-phosphate diet brings it back.
6. 2014
   Cognition enters the story
   KL-VS heterozygosity is linked to better cognitive scores in human cohorts, and klotho-overexpressing mice outperform controls on learning and memory tasks.
7. 2023
   Aged monkeys
   A single low dose of rhesus klotho protein improves memory performance in aged rhesus monkeys; a high dose does not.
8. 2025–2026
   First registered human studies
   A plasmid klotho gene therapy and an alpha-klotho mRNA candidate are registered as phase 1 studies. Neither has posted results.

§What klotho actually does

The function established beyond dispute is mineral handling. Osteocytes secrete FGF23 in response to phosphate intake; FGF23 cannot signal usefully on its own, because the FGF receptors it must reach have low affinity for it. Membrane α-klotho, abundant in the renal tubule, converts a canonical FGF receptor into a high-affinity FGF23 receptor, and the resulting signal reduces phosphate reabsorption and suppresses active vitamin D.¹ Remove klotho and the system fails in the direction of severe hyperphosphatemia.

This is also why klotho is a nephrology subject before it is a longevity subject. Chronic kidney disease is characterised as a state of klotho deficiency, with falling renal expression and falling circulating levels tracking disease progression, vascular calcification and cardiac hypertrophy.¹ Whether that deficiency is a cause of the damage or a readout of a failing kidney is the same question the aging literature asks in a different setting.

Is the klotho-null mouse aging, or poisoned by phosphate?

Klotho-null mice retain phosphate to a degree that is lethal on its own. Crossing them with mice lacking the renal phosphate transporter NaPi2a lowered serum phosphate, restored fertility and body weight, suppressed ectopic calcification and prolonged survival; feeding those double-knockouts a high-phosphate diet brought the premature-aging features back.³ On that reading the 1997 phenotype is severe mineral disease that mimics old age, not accelerated aging. Proponents of the longevity interpretation answer that phosphate toxicity is itself one of the mechanisms by which tissues age, which keeps klotho central without requiring it to act through any separate anti-aging pathway.

§The lifespan claim in mice

The claim that klotho extends life comes from one experiment and its descendants. Transgenic mice engineered to overexpress klotho lived longer than wild-type littermates, and the authors traced the effect to repression of insulin and IGF1 signalling, the pathway already implicated in longevity by work in nematodes and mice associated with Cynthia Kenyon and by the physiology of Caloric restriction.⁴ Klotho thereby entered the small set of single-gene manipulations that lengthen mouse life, alongside the drug effects catalogued for Rapamycin.

Two features of that experiment limit what it licenses. The animals carried the extra klotho from conception, so the result describes a lifelong genetic condition rather than a treatment given to an adult. And the mice were laboratory mice, whose lifespan is easier to extend than a human's for reasons that have embarrassed the field before, most visibly in the divergence between mouse and human telomere biology. Klotho sits in the same category as most entries in the Hallmarks of aging literature: a real mouse effect of undetermined human relevance, which is the problem the Geroscience hypothesis exists to address.

§Evidence in people

Human work has taken two forms, both observational.

Genotype. KL-VS is a klotho haplotype whose carriers were reported to be overrepresented among long-lived individuals when heterozygous and underrepresented when homozygous. A 2014 study combined that genetic signal with mouse experiments, reporting better cognitive scores in heterozygous carriers across several cohorts and better learning and memory in klotho-overexpressing mice, with enrichment of the NMDA receptor subunit GluN2B as the proposed mechanism.⁵ The finding is the origin of nearly all subsequent interest in klotho and cognition, including its appearance in discussions of Genetic enhancement of cognition.

Replication has been mixed in both directions. In 1,480 Danes aged 92 to 100, KL-VS heterozygotes performed worse than non-carriers, while other variants in the same gene were associated with better cognition.⁶ A comparison of long-lived individuals from the Newcastle 85+ Study against UK Biobank controls found no reliable support for KL as a longevity locus, with the two candidate associations it did detect failing to replicate in the remainder of the Biobank sample.⁷

Serum levels. Circulating klotho has been measured in general-population cohorts. Among roughly 10,000 American adults aged 40 to 79 in the National Health and Nutrition Examination Survey, the lowest band of serum klotho carried about a 31% higher risk of death over a mean follow-up of just under five years than the highest, with the association stronger among people not meeting physical-activity guidelines.⁸ That last detail is a reminder of how much such a measure absorbs: kidney function, inflammation and fitness all move it, which is why klotho is discussed alongside Aging biomarkers and Inflammaging rather than as an independent cause.

What the human data cannot show

Every human klotho finding is a correlation. Low serum klotho in an unhealthy person is at least partly a consequence of reduced kidney function, so the mortality association is compatible with klotho being a marker rather than a driver. Assay method matters too: immunoprecipitation-based measurement tracks kidney function considerably better than the commercial ELISAs most cohort studies use, which complicates comparison across papers. Nothing short of administering klotho and measuring an outcome will separate the readings, and that experiment has not been reported in people.

§Giving klotho: mice, monkeys, and the first human studies

Administration studies bypass the genetics by injecting the protein. In mice, peripherally delivered klotho fragments improved cognition and synaptic measures. The most-cited extension of that work gave rhesus klotho protein to aged rhesus monkeys and reported improved memory performance after a single low dose, with no benefit at a high dose.⁹ The dose-response inversion is unusual, the group was small, and the study measured memory rather than lifespan or any Healthspan endpoint. It remains the closest thing to a human-relevant demonstration.

Two human studies were on the registry by 2026, neither with results.¹⁰ Minicircle, a company that dosed volunteers with a plasmid follistatin construct in an earlier and widely reported episode of offshore Biohacking and grinders, registered a 24-person, single-arm, non-placebo-controlled phase 1 of an injectable klotho plasmid, with the record stating that administration occurs outside United States jurisdiction while assessments happen in Texas. Klothea Bio registered a randomised, placebo-controlled phase 1b of an α-klotho mRNA formulated in Lipid nanoparticles. The contrast between the two designs is the whole argument about how Gene therapy for aging should be tested, and it is visible in the registry entries themselves.

Delivery is unsettled. Klotho has been pursued as recombinant protein, as mRNA, and as a gene delivered by AAV vectors under the general approach described in Somatic gene therapy. Each raises a different durability and reversibility question, and none has cleared it. Two authors of the monkey study founded a company to continue developing klotho therapeutics, and a corporate sponsor of that work held patent applications on klotho for cognition.⁹ Commercial interest in the molecule runs well ahead of the human evidence for it, a pattern the field also produced around Senolytics and around young-blood transfusion.

§Outlook

The near-term test is not lifespan. It is whether a klotho candidate can move a measurable endpoint in a population where klotho is demonstrably depleted, which points at kidney disease rather than at healthy aging, and where an outcome can be read in months rather than decades. A cognitive endpoint in an older population is the second candidate, and the one the monkey work was designed to justify.

Klotho follows a recurring shape in longevity biology. A gene is found through a mouse phenotype, acquires a mythological name and a hormone story, and accumulates human association studies that neither confirm it nor kill it, while the mechanism actually established turns out to be a specific physiological job with a clinical constituency of its own. The same gap between animal phenotype and human function has already played out for Myostatin inhibition, where it was closed by trials rather than by more cohorts.

The unanswered question is narrower than the one the field usually poses. Klotho deficiency demonstrably harms a mouse and accompanies kidney disease in a person; nobody has shown that a healthy adult with ordinary klotho levels has anything to gain from more of it. No Biological age estimate, epigenetic clock, or association between fitness and klotho of the kind discussed under Exercise as a geroprotector can decide that, because the deficient and the merely average are not the same population, and only one of them has ever been rescued.

§See also

• Gene therapy for aging
• Genetic enhancement of cognition
• Hallmarks of aging
• Geroscience hypothesis
• Aging biomarkers
• Parabiosis and young blood

§References